[-] Show simple item record

dc.contributor.authorDiehr, Sabinaeng
dc.contributor.authorMijal, Saraeng
dc.contributor.authorNashelsky, Joaneng
dc.date.issued2005-07eng
dc.description.abstractRaloxifene (60 mg daily for three years) will prevent one vertebral fracture, including asymptomatic fractures, for every 46 postmenopausal women with osteoporosis or presence of previous vertebral fractures. Raloxifene has not been shown to prevent nonvertebral fractures. It is unclear if longer duration of treatment is warranted, or whether this risk reduction is sustained after discontinuation of treatment. [Strength of recommendation: A, based on systematic reviews of randomized controlled trials (RCTs)]eng
dc.identifier.citationAmerican Family Physician, 72(1) 2005.eng
dc.identifier.urihttp://hdl.handle.net/10355/3950eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2005 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectbone resorptioneng
dc.subjectnonvertebral fractureseng
dc.subjectmenopauseeng
dc.subjectbreast cancereng
dc.subject.lcshRaloxifeneeng
dc.subject.lcshMenopauseeng
dc.subject.lcshOsteoporosiseng
dc.subject.lcshFractures -- Preventioneng
dc.subject.lcshBreast -- Cancereng
dc.titleRaloxifene for Prevention of Osteoporotic Fractureseng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record